HER2+ Gastric Cancer Market Growth & Trends

The HER2+ gastric cancer market size is estimated to reach USD 2,318 million by 2034, registering a CAGR of 14.20% from 2025 to 2034, according to a new report by DelveInsight, a pharmaceutical market research firm. Rising incidence of gastric cancer and expanding adoption of targeted therapies are the primary factors propelling market growth. Moreover, increasing advancements in HER2-targeted treatments, companion diagnostics, and innovative antibody-drug conjugates (ADCs) by pharma companies include ALX Oncology, Jazz Pharmaceuticals, BeiGene, Zymeworks, Enliven Therapeutics, Ambrx and NovoCodex, AstraZeneca, Shanghai Henlius Biotech, AbClon, KLUS Pharma, Pfizer, and Bayer, among others, are driving the expansion of the HER2+ gastric cancer market.

The strong HER2+ Gastric Cancer clinical pipeline demonstrating positive clinical results is a major factor driving the therapeutic market. For instance, in January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer.

The growing prevalence of gastric cancer globally is further fueling the HER2+ gastric cancer market growth, as HER2-positive cases represent approximately 15-30% of all gastric cancer cases. Gastric cancer represents the fifth most prevalent malignant tumor globally, with the highest incidence rates observed in Eastern Asia and Eastern Europe. Japan has the highest rate of gastric cancer among the seven major markets, with around 130K cases in 2024. In the United States, about 15% of people with advanced gastric cancer and 30% of people with advanced GEJ cancer have HER2+ tumors.

Innovative treatment developments and regulatory approvals are playing a crucial role in boosting market growth by expanding treatment options and improving patient outcomes. For instance, in March 2025, Merck's pembrolizumab (Keytruda), combined with trastuzumab and chemotherapy, was approved by the FDA for adults with HER2+, unresectable or metastatic gastric/gastroesophageal junction (GEJ) cancer expressing PD-L1. Furthermore, in August 2025, the FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim), further enriching the HER2+ gastric cancer armamentarium.

Moreover, rising investments in precision oncology and biomarker-driven therapies are providing lucrative opportunities for key players. The current treatment landscape has evolved significantly with the approval of HERCEPTIN in the first-line setting, followed by the integration of KEYTRUDA in combination with trastuzumab and chemotherapy, and the subsequent approval of ENHERTU in the second-line setting.

Request a free sample copy or view report summary: HER2+ Gastric Cancer Market Report

HER2+ Gastric Cancer Market Report Highlights

• To keep up with current market trends, DelveInsight takes KOLs and SME's opinions working in the domain through primary research to fill the data gaps and validate our secondary research.
• The epidemiology chapter provides historical as well as forecasted epidemiology segmented by total incident cases of gastric cancer (including GEJ), gender-specific cases of gastric cancer (including GEJ), stage-specific cases of gastric cancer (including GEJ), total incident cases of HER2+ gastric cancer (including GEJ), and total incident cases of advanced HER2+ gastric cancer (including GEJ), in the 7MM
• The report provides an edge to pharma executives by understanding the market trends through SWOT analysis and expert insights, patient journey, and treatment preferences that help in shaping and driving the 7MM HER2+ gastric cancer market.
• The report contains an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.

HER2+ Gastric Cancer Market Segmentation

DelveInsight has segmented the HER2+ gastric cancer market based on therapy type, treatment line, end-user, and region:

HER2+ Gastric Cancer Treatment

• Endoscopic mucosal resection

• Surgery
• Gastrectomy
• Radiation therapy
• Chemotherapy
• Targeted therapy
  • Ramucirumab
  • Regorafenib
  • Trastuzumab
  • Trastuzumab deruxtecan
• Immunotherapy
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

HER2+ Gastric Cancer Drug Class Analysis

• HER2-directed Therapies
• PD-1 Inhibitor

HER2+ Gastric Cancer End-User Outlook (Revenue, USD Million, 2025 - 2034)

• Hospitals and Specialty Clinics
• Cancer Treatment Centers
• Others

HER2+ Gastric Cancer Regional Outlook (Revenue, USD Million, 2025 - 2034)

• The U.S.
• Europe (Germany, France, Italy, Spain, the UK)
• Asia Pacific (Japan)

The HER2+ gastric cancer market is experiencing robust growth driven by technological advancements in targeted therapy, increasing disease prevalence, and expanding pipeline of innovative treatments. The overall market is projected to grow significantly, driven by increasing biomarker testing, better patient selection, and continued advancements in HER2-targeted ADCs, bispecific antibodies, and novel immune-based approaches.

The comprehensive DelveInsight HER2-directed Therapies Market Report provides pharmaceutical executives with the detailed market intelligence, competitive analysis, and strategic insights necessary to navigate this complex and rapidly evolving therapeutic landscape.